On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE: AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.

Amneal + Impax at-a-Glance

OUR PORTFOLIO FOCUS

Generics

Specialty Products

Biosimilars

COMPANY FOUNDING

2002

TOTAL EMPLOYEES

~6,500

GENERIC PRODUCTS

~200

SPECIALTY PRODUCTS

5

GENERICS PIPELINE

~280

SPECIALTY PIPELINE

Investigational Drug

IPX203

BIOSIMILARS PIPELINE

1

Product filed

1

Near-term filing opportunity

1

Under Development

MANUFACTURING  CAPACITY

~20

Billion units

ANNUAL R&D  INVESTMENT

~10%

of annual revenues

Broad Capabilities Across Dosage Forms

ORAL SOLIDS & LIQUIDS

  • IR/ER tablets
  • Hard Gelatin Capsules
  • Softgel Capsules
  • Hormonals
  • Controlled Substances
  • Suspensions/Solutions

TOPICALS

  • Gels
  • Creams
  • Ointments
    & Devices
  • Hormonals

INJECTABLES & STERILE

  • Peptides
  • Microspheres
  • Liposomes
  • Hormonals
  • General Injectables
  • Oncology Injectables
  • Ophthalmics
  • Otics

TRANSDERMALS

  • Matrix
  • Hydrogel
  • Form Fill Seal
  • Hormonals

RESPIRATORY

  • Metered Dose
  • Dry Powder
  • Nasal Spray Pumps
  • BFS Inhalation